Publications
PrecivityAD® and PrecivityAD2™ Tests - Research & Trials
Impact on Clinical Trial Enrollment, Design and Economics
Walter S, Langford O, Jimenez-Maggiora GA, et al. The AlzMatch Pilot Study - Feasibility of remote blood collection of plasma biomarkers for preclinical Alzheimer’s disease trials. J Prev Alzheimers Dis. 2024;11(5):1435-1444. doi.org/10.14283/jpad.2024.101
Angioni D, Hansson O, Bateman RJ, et al. Can We Use Blood Biomarkers as Entry Criteria and for Monitoring Drug Treatment Effects in Clinical Trials? A Report from the EU/US CTAD Task Force. J Prev Alzheimers Dis. 2023. doi.org/10.14283/jpad.2023.68
Schindler SE, Li Y, Li M, et al. Using Alzheimer’s disease blood tests to accelerate clinical trial enrollment. Alzheimers Dement. 2023;19(4):1175-1183. doi:10.1002/alz.12754
Amyloid Accumulation Over Time
Li Y, Yen D, Hendrix RD, et al. Timing of biomarker changes in sporadic Alzheimer disease in estimated years from symptom onset. Ann Neurol. 2024;95:951-965. doi:10.1002/ana.26891
Analyte Performance
Bornhorst JA, Lundgreen CS, Weigand SD, et al. Quantitative Assessment of the Effect of Chronic Kidney Disease on Plasma P-Tau217 Concentrations. Neurology. 2025;104(3):e210287. doi:10.1212/WNL.0000000000210287
Devanarayan V, Charil A, Horie K, et al. Plasma pTau217 ratio predicts continuous regional brain tau accumulation in amyloid-positive early Alzheimer's disease. Alzheimer's Dement. 2024;1-15. doi:10.1002/alz.14411
Schindler SE, Petersen KK, Saef B, et al. Head-to-head comparison of leading blood tests for Alzheimer's disease pathology. Alzheimer’s Dement. 2024;20:8074–8096. doi:10.1002/alz.143
Devanarayan V, Doherty T, Charil A, et al. Plasma pTau217 predicts continuous brain amyloid levels in preclinical and early Alzheimer's disease. Alzheimer’s Dement. 2024;20(8):5617-5628. doi:10.1002/alz.14073
Meeker KL, Luckett PH, Barthélemy NR, et al. Comparison of cerebrospinal fluid, plasma and neuroimaging biomarker utility in Alzheimer's disease. Brain Commun. 2024;6(2):fcae081. Published 2024 Mar 15. doi:10.1093/braincomms/fcae081
Bayat S, Roe CM, Schindler S, et al. Everyday Driving and Plasma Biomarkers in Alzheimer's Disease: Leveraging Artificial Intelligence to Expand Our Diagnostic Toolkit. J Alzheimers Dis. 2023;92(4):1487-1497. doi:10.3233/JAD-221268
Wisch J, Gordon B, Boerwinkle A, et al. Predicting continuous amyloid PET values with CSF and plasma Aβ42/Aβ40. Alzheimers Dement. 2023;15(1):e12405. Published 2023 Mar 2. doi:10.1002/dad2.12405
Hartz SM, Mozersky J, Schindler SE, et al. A flexible modeling approach for biomarker‐based computation of absolute risk of Alzheimer’s disease dementia. Alzheimers Dement. 2023;19(4):1452-1465. doi:10.1002/alz.12781
Winston CN, Langford O, Levin N, et al. Evaluation of blood-based plasma biomarkers as potential markers of amyloid burden in preclinical Alzheimer’s disease. J Alzheimers Dis. 2023; 92(1), 95–107. doi.org/10.3233/JAD-221118
Aschenbrenner AJ, Li Y, Henson RL, et al. Comparison of plasma and CSF biomarkers in predicting cognitive decline. Ann Clin Transl Neurol 2022; 9(11):1739-1751. doi:10.1002/acn3.51670
Rafii MS, Sperling RA, Donohue MC, et al. The AHEAD 3-45 Study: Design of a prevention trial for Alzheimer's disease. Alzheimers Dement. 2023;19(4):1227-1233. doi/10.1002/alz.12748
Treatment Monitoring (Research Use)
Sims JR, Zimmer JA, Evans CD, et al. Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ2 Randomized Clinical Trial. JAMA. 2023. Published online July 17, 2023.* doi:10.1001/jama.202313239
van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in Early Alzheimer's Disease. N Engl J Med. 2023;388(1):9-21. doi:10.1056/NEJMoa2212948
McDade E, Cummings JL, Dhadda S, et al. Lecanemab in patients with early Alzheimer's disease: detailed results on biomarker, cognitive, and clinical effects from the randomized and open-label extension of the phase 2 proof-of-concept study. Alzheimers Res Ther. 2022;14(1):191. Published 2022 Dec 21. doi:10.1186/s13195-022-01124-2
Swanson CJ, Zhang Y, Dhadda S, et al. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody [published correction appears in Alzheimers Res Ther. 2022 May 21;14(1):70]. Alzheimers Res Ther. 2021;13(1):80. Published 2021 Apr 17. doi:10.1186/s13195-021-00813-8
* Publication includes Precivity-p-tau217 analyte measurements (part of PrecivityAD2 rather than PrecivityAD) used in longitudinal monitoring